|
Low-Value PCI, Valvosoft’s AS Ultrasound, and LVEDD’s Value
By Viktor Zarev, Virginia Hunt
August 13, 2026
|
|
|
|
|
Together with
|
|
|
|
“A number of hospitals offer medical ethics training but there’s no evidence that completing this training improves your ability to think about any problem in medicine, let alone an ethical problem. I would encourage the groups that run these training programs to formally evaluate them. Evaluation would center on real clinical actions and not the results of some survey or test.”
|
|
Vinay Prasad, MD, MPH
|
|
|
Supply and demand in healthcare isn’t always clear cut. Sometimes more physician supply met by less patient demand leads to patients getting treatments they don’t really need. In those cases, it’s rarely even the physician’s fault.
Thanks for reading,
Vik
|
|
|
Surgeries & Interventions
|
|
|
|
|
|
The old adage that “built capacity gets used” applies to cardiology too. A Lown Institute study found that regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.
- PCI is lifesaving in ACS but leads to lower-value outcomes in stable CAD.
- Specifically, trials like COURAGE and ORBITA suggest it doesn’t reduce mortality versus medication.
- What makes this Lown study interesting is the disproportionate part, since the analysis is among the first to show that physician supply drives low-value care specifically.
So how does provider density correlate with overuse? Researchers analyzed 100% of Medicare fee-for-service and Medicare Advantage data from 2019–2021, to find the share of a hospital’s PCIs performed on patients with stable CAD.
They then stratified the results from the lowest- to highest-supply regions, finding PCI overuse climbed as interventional cardiologist density increased.
- Total PCIs doubled from 15.1 to 31.3 per 1,000 Medicare beneficiaries.
- Low-value PCIs climbed from 2.6 to 7.9 per 1,000.
- Each additional PCI provider per region was associated with ~225 extra procedures.
- Provider supply explained about 90% of regional variance in total PCI use.
In other words, the idea that expanding provider supply lowers costs through competition looks shaky in light of this data.
Here’s the kicker, it’s a structural problem. Market incentives push hospitals to open interventional cardiac programs near competitors that already offer them, multiplying capacity without actually expanding access.
As robust as the analysis is, the study’s limits are worth stating plainly. This is observational data and can’t prove causation.
- Claims-based measures can’t capture patient details like coronary anatomy or prior interventions, and these are Medicare beneficiaries, not all patients in a system.
- Thus, the label of “lower-value” applies to the population level, rather than to individual patients.
The Takeaway
More interventionists, more problems, am I right? But in all seriousness, the data from this Lown study points to a reality of the American health system – when profit drives procedural volume, care capacity doesn’t lead to better outcomes, just more lucrative ones.
|
|
How Us2.ai Improves CA Screening
Cardiac amyloidosis may not be as rare as previously thought, with early and accurate detection becoming increasingly critical for treatment. Read about how the AI-SCREEN-CA study implemented Us2.ai’s automated CA reporting and AI-based pattern recognition analysis, leading to better disease screening at scale.
|
|
How Automated MRI Software Transformed Radiology Regional
Radiology Regional recently integrated automated MRI scanning software into their imaging practice imaging. Hear from their team how automating CMR scans streamlined their practice and enhanced patient care.
|
|
ALL‑RISE Trial Results Are In
The CathWorks FFRangio™ system met noninferiority to wire-based physiology for MACE at one year with statistically significant improvement in resource utilization and reduced procedure time. CathWorks FFRangio™ system is the new standard in coronary physiology. See the ALL-RISE data.
The information provided by the CathWorks FFRangio™ system is intended to be used by a qualified clinician in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional evaluation. Source: Fearon et al. NEJM 2026. doi: 10.1056/NEJMoa2600949
|
|
- Ventricle Size for Mortality Risk: A nationwide Chinese cohort of 274k hospitalized heart failure patients found a “U-shaped” association between left ventricular end-diastolic diameter (LVEDD) and mortality. Both abnormally small and large ventricles independently predicted elevated all-cause mortality (aHR: 1.32, 1.38). Meanwhile, the sex-specific ideal LVEDD thresholds were 47mm for men and 43mm for women. The authors argue LV size should be integrated into routine risk stratification, challenging the conventional focus on dilation alone.
- US for AS: Too frail for intervention? Ultrasound waves might be the answer. A single-arm study of 60 frail, elderly patients (median age 88) found that Valvosoft’s non-invasive ultrasound therapy for AS is safe and feasible outside the cath lab. The study met its primary safety endpoint with no cerebrovascular events, and 86% of patients saw NYHA class improvement or stabilization at 30 days. Notably, aortic valve area increased over time, suggesting reverse valvular remodeling (0.67 to 0.81cm² at 12 months).
- FDA Clears Ultrasound Contrast Injector: Bracco Imaging earned FDA clearance for VueJect, the company’s first ultrasound contrast delivery system dedicated to cardiac imaging. The injector is designed to simplify echocardiography contrast administration through improved workflow efficiency and less operator variability while supporting continuous contrast levels. Bracco is better known in the CVUS space for its Lumason ultrasound contrast agent (sold as SonoVue outside the U.S.)
- DMD Heart Scarring & Stem Cells: Greenstone Biosciences received a Catalyze R61 award from the NIH’s NHLBI to discover drugs for myocardial fibrosis and dilated cardiomyopathy in Duchenne muscular dystrophy (DMD). Using its iPSC biobank, patient-derived cardiomyocyte models, proteomics, and AI, the program targets DMD heart scarring, for which no approved therapy exists. Though still early, the program has the potential to advance to a second funding phase, which would be a sign that stem cell heart therapies are gaining recognition.
- Impella’s Latest Sheath Recall: Two months after the FDA’s safety warning regarding J&J’s Impella heart pump introducer sheaths, a Class I recall has been issued for some batches of the device. The FDA feels the upgrade to Class I is warranted given the potentially life-threatenting risks caused by leaky sheaths. While the Impella sheaths don’t need to be returned, the FDA recommends close monitoring or device exchange. This marks the seventh recall in just over a year for the Impella platform.
- ACCESSible Tech for Surgery Centers: ACCESS partnered with Johnson & Johnson to help ambulatory surgery centers adopt the newest cardiac technology. While ASCs can be easier to access and up to 40-60% cheaper than hospitals, many don’t have state-of-the-art tools for ablation and mapping on-hand in the same way hospitals do. The partnership is an example of medtech companies taking advantage of the CMS’ decision to add cardiac ablations to the ASC covered procedures list this past January.
- Mounjaro’s CVD Protection: Eli Lilly’s GLP-1 may benefit yet another facet of heart health for patients with diabetes. A BMJ study examined 53k patients with diabetes and ASCVD, finding that those taking Mounjaro were 32% less likely to experience MACE compared to placebo. This trial adds to the mounting evidence of GLP-1’s CV benefits, following Mounjaro’s improved HF outcome data and Novo’s SELECT and STRIDE trials for semaglutide that proved GLP-1s can help avoid MACE and improve PH quality of life.
- Global Warming Versus Heart Health: Record-high temperatures and smoky air can each be harmful, but, taken together, they pack an even more powerful punch to heart health. Data from nearly 6M death records published in JACC showed compound exposure to heat waves and fire-related air pollution increased the risk of cardiovascular mortality by 11.5%, more than heat (8.3%) or smoke (1.4%) alone. As global warming continues, the synchronicity of these hazards is expected to increase too.
- Mitochondria After Cardiac Arrest: Considering that about 90% of out-of-hospital cardiac arrest patients don’t survive, helping the heart recover after it stops is key. Aiming to address this, a large-animal study from Northwell Health’s Feinstein Institutes found that a single intravenous dose of mitochondria transplantation dramatically improved heart recovery after cardiac arrest. The treatment strengthened the heart’s pumping, raised blood pressure without vasopressors, and reduced early damage to the brain, heart, lungs, liver, and kidneys, pointing toward a disease-modifying strategy for post-cardiac arrest syndrome.
- Braveheart Goes Public: Less than a year after its official launch, Braveheart Bio banked a $440M IPO to fund two Phase 3 trials of its cardiac myosin inhibitor, BHB-1893. The proceeds beat Braveheart’s expectations by $165M, reflecting optimism that BHB-1893 could compete with Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo for treating obstructive hypertrophic cardiomyopathy. With no approved treatment for nHCM, investors are also bullish BHB-1893 could differentiate itself by becoming the condition’s first FDA-approved drug.
- Phase 3 Miss, Thought Sicker Patients Benefit: In a hit to its pulmonary hypertension pipeline, Tenax Therapeutics’ Phase 3 LEVEL trial for TNX-103 (oral levosimendan) in PH-HFpEF missed its primary endpoint. Following analysis, the drug ultimately showed no significant improvement in 6-minute walk distance versus placebo. However, prespecified subgroups with greater disease burden fared better, with a 26.3-meter walk improvement in patients below the 333-meter baseline median. This came alongside a striking 49% NT-proBNP reduction across the subgroup. Tenax plans to request an FDA Type C meeting.
|
|
cvi42’s Real World Results
Consistency of measurements over time is of utmost importance for clinical interpretation and follow-up. Read about how cardiac imagers are using Circle Cardiovascular Imaging’s cvi42 platform to dramatically reduce manual segmentation by up to 60%.
|
|
State-of-the-Art Cardiac Monitoring at Scale
Cleared for 13 different heart rhythm interpretations, AccurKardia’s AccurECG 2.0 shortens the time from an arrhythmia incident to clinical intervention. Watch here to find out how AccurKardia and Specialized Medical are teaming up to bring the AccurECG 2.0 technology to clinicians across the U.S.
|
|
9 Merge Cardio Features to Change Your Cardiology Workflows
Having the right tools is essential for efficient cardiology imaging workflows and delivering exceptional patient care. Read this article on how Merge Cardio can make the biggest difference to your imaging workflows, care team user experiences, and patient care delivery.
|
|
- What Every Cardiologist Needs to Watch for in Heart Failure: Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.
- Earlier Detection, Better Outcomes: When it comes to heart disease, early detection is crucial to a patient’s long-term health. Learn more about how Fujifilm helps clinicians achieve that with the Lisendo 880 cardiovascular ultrasound system’s unique solutions that detect early abnormalities seen in heart failure, while offering insight into cardiac functions and groundbreaking hemodynamic analysis.
- How to Streamline Your Reporting Process: Like many medical centers, Baystate lacked a single cardiovascular database to streamline the documentation process and ensure accuracy. Read this Optum case report to learn how Baystate improved its percentage of unsigned charges within a 5-day window from a high of 89% to under 10%.
- Making the Leap to Outsource Post-Processing: Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
- Telemedicine Isn’t About Technology. It’s About People. With temporary telehealth rules expiring, millions of Medicare patients may lose their ability to see their doctors remotely. Read why Monebo and the Alliance for Connected Care are urging Congress to make telemedicine a permanent part of the healthcare system.
|
|
|
|
|
